Raymond James downgraded shares of Amneal Pharmaceuticals (NYSE:AMRX) from a strong-buy rating to an outperform rating in a report published on Wednesday morning, The Fly reports. The firm currently has $8.50 price objective on the stock, down from their prior price objective of $13.00.
Other equities analysts have also issued research reports about the stock. Piper Jaffray Companies set a $92.00 target price on shares of Wintrust Financial and gave the stock a buy rating in a research report on Monday, July 8th. ValuEngine lowered shares of Whiting USA Trust II from a hold rating to a sell rating in a research report on Tuesday, May 7th. Barclays restated a hold rating on shares of Bank of Montreal in a research report on Tuesday, June 11th. BMO Capital Markets upped their target price on shares of Sun Life Financial from C$58.00 to C$60.00 in a research report on Friday, May 10th. Finally, Cantor Fitzgerald restated an overweight rating and set a $130.00 target price (up previously from $116.00) on shares of Zoetis in a research report on Wednesday, June 12th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of Hold and a consensus price target of $14.58.
AMRX opened at $3.70 on Wednesday. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of 4.35, a P/E/G ratio of 0.25 and a beta of 1.50. Amneal Pharmaceuticals has a 1-year low of $3.69 and a 1-year high of $24.48. The stock has a 50 day moving average price of $7.12. The company has a current ratio of 2.11, a quick ratio of 1.37 and a debt-to-equity ratio of 3.44.
In other Amneal Pharmaceuticals news, VP Andrew S. Boyer acquired 19,000 shares of the stock in a transaction on Monday, May 13th. The stock was acquired at an average price of $9.46 per share, for a total transaction of $179,740.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Pradeep Bhadauria acquired 7,000 shares of the stock in a transaction on Wednesday, May 15th. The shares were acquired at an average price of $8.48 per share, with a total value of $59,360.00. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 41,000 shares of company stock valued at $387,300. 26.34% of the stock is owned by company insiders.
A number of hedge funds have recently added to or reduced their stakes in the business. Quantamental Technologies LLC lifted its position in Amneal Pharmaceuticals by 34.0% during the first quarter. Quantamental Technologies LLC now owns 6,700 shares of the company’s stock valued at $95,000 after purchasing an additional 1,700 shares during the last quarter. Legal & General Group Plc lifted its position in Amneal Pharmaceuticals by 5.5% during the fourth quarter. Legal & General Group Plc now owns 34,505 shares of the company’s stock valued at $467,000 after purchasing an additional 1,810 shares during the last quarter. Oppenheimer Asset Management Inc. lifted its position in Amneal Pharmaceuticals by 11.1% during the first quarter. Oppenheimer Asset Management Inc. now owns 18,269 shares of the company’s stock valued at $259,000 after purchasing an additional 1,828 shares during the last quarter. Brinker Capital Inc. lifted its position in Amneal Pharmaceuticals by 11.1% during the first quarter. Brinker Capital Inc. now owns 21,110 shares of the company’s stock valued at $299,000 after purchasing an additional 2,105 shares during the last quarter. Finally, Bessemer Group Inc. bought a new position in Amneal Pharmaceuticals during the fourth quarter valued at $34,000. Institutional investors and hedge funds own 36.05% of the company’s stock.
Amneal Pharmaceuticals Company Profile
Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. It operates through two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories.
Receive News & Ratings for Amneal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amneal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.